Blackstone Life Sciences to invest up to $250 million in Autolus Therapeutics to develop obe-cel in adult Acute Lymphoblastic Leukemia (ALL) and advance broader platform

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/29/2026

1. NVDA
2. SPCX
3. META
4. MDB
5. USO
6. MU
7. KOD
8. MIRM
9. LLY
10. SPY

Go back to Blackstone Life Sciences to invest up to $250 million in Autolus Therapeutics to develop obe-cel in adult Acute Lymphoblastic Leukemia (ALL) and advance broader platform
(NASDAQ: AUTL) Delayed: 1.86 --0 (-0%)
Previous Close $1.86    52 Week High $ 
Open $1.82    52 Week Low $ 
Day High $1.89    P/E N/A 
Day Low $1.79    EPS $ 
Volume 1,399,647       

THE BLACKSTONE GROUP L.P (NYSE: BX) Delayed: 114.56 -3.86 (3.26%)
Previous Close $118.42    52 Week High $32.07 
Open $117.00    52 Week Low $22.31 
Day High $117.35    P/E 101.38 
Day Low $113.88    EPS $1.13 
Volume 8,078,893